Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain NVAX message board posts where the ticker symbol NVAX has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest NVAX SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001144204-18-043309 (34 Act)  Size: 117 KB
2018-08-09 000-26770
181005340
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001144204-18-042849 (34 Act)  Size: 5 MB
2018-08-08 000-26770
181001848
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-044767 Size: 4 KB
2018-08-01
S-8  Documents Securities to be offered to employees in employee benefit plans
Acc-no: 0001144204-18-041390 (33 Act)  Size: 84 KB
2018-08-01 333-226498
18985416
8-K  Documents Current report, item 1.01
Acc-no: 0001144204-18-039633 (34 Act)  Size: 19 KB
2018-07-24 000-26770
18966693
8-K  Documents Current report, item 5.07
Acc-no: 0001144204-18-034442 (34 Act)  Size: 28 KB
2018-06-15 000-26770
18902797
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-18-006330 (34 Act)  Size: 11 KB
2018-06-12 000-26770
18890131
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-030109 Size: 5 KB
2018-05-15
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-030108 Size: 4 KB
2018-05-15
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-030107 Size: 4 KB
2018-05-15
More NVAX SEC Filings


Related news from
Wed, 15 Aug 2018
10:02:00 +0000
5 Promising Vaccines in Development -- and the Stocks Poised to Profit From Them
Nearly $5 billion in combined annual sales could be on the way from these top vaccines in development.
Thu, 09 Aug 2018
16:07:38 +0000
Why Novavax, Inc. Shares Are Soaring Today
The clinical-stage biotech provided good news for two key vaccines in its pipeline.
Thu, 09 Aug 2018
12:00:00 +0000
Today's Research Reports on Trending Tickers: Novavax and INSYS Therapeutics
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / U.S. equities were mixed on Wednesday as a result of disappointing corporate earnings combined with the latest trade news. The Dow Jones Industrial Average ...
Thu, 09 Aug 2018
00:30:12 +0000
Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates
Novavax (NVAX) delivered earnings and revenue surprises of 0.00% and 4.85%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Wed, 08 Aug 2018
23:22:28 +0000
Novavax: 2Q Earnings Snapshot
On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 12 cents. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Wed, 08 Aug 2018
20:05:00 +0000
Novavax Reports Second Quarter 2018 Financial Results
Novavax Delivers on Key Milestones Supporting its 2018 Objectives. Company to Host Conference Call Today at 4:30 pm ET. GAITHERSBURG, Md., Aug. 08, 2018-- Novavax, Inc. today announced its financial results ...
Wed, 08 Aug 2018
18:30:00 +0000
Novavax, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Novavax, Inc. (NASDAQ: NVAX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern Time. To ...
Wed, 01 Aug 2018
20:05:00 +0000
Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 8, 2018
GAITHERSBURG, Md., Aug. 01, 2018-- Novavax, Inc. today announced it will report its second quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, August ...
Sat, 28 Jul 2018
12:00:00 +0000
How to Invest in Clinical-Stage Biotechs Without Losing Money
Clinical-stage biotechs can wreak havoc on your portfolio. Here's one approach that can limit the potential damage while still allowing you to take a long-term approach to capital appreciation.
Thu, 26 Jul 2018
11:55:00 +0000
Consolidated Research: 2018 Summary Expectations for At Home Group, Royal Bank Of Canada, Curis, Novavax, HNI, and Freshpet — Fundamental Analysis, Key Performance Indications
NEW YORK, July 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of At ...
Mon, 23 Jul 2018
13:18:00 +0000
Top 3 Healthcare Penny Stocks for 2018
The healthcare industry can be precarious for stocks of large companies, much less penny stocks. Of course, small-cap healthcare companies can be nudged out of the market by big competitors, and they can simply become unable to service debt when products and services don't sell quickly enough. None of these are new companies – they have made progress in developing products and finding the marketing outlets that are needed to sustain them.
Thu, 19 Jul 2018
11:29:00 +0000
Better Buy: Novavax, Inc. vs. Pfizer
Novavax and Pfizer have been chronic underachievers, but their stocks may soon perk up. Here's a look at which stock is the better buy right now.
Thu, 12 Jul 2018
13:25:00 +0000
Why Novavax Stock Buckled in June
Novavax's stock got blasted by geopolitical headwinds last month, but that doesn't mean it's now a bargain.
Thu, 05 Jul 2018
11:25:00 +0000
Free Technical Reports on Novavax and Three Additional Biotech Equities
WallStEquities.com has initiated research reports on the following Biotechnology stocks: Nabriva Therapeutics PLC (NASDAQ: NBRV), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Novavax Inc. (NASDAQ: NVAX), and Novo Nordisk A/S (NYSE: NVO). All you have to do is sign up today for this free limited time offer by clicking the link below.
Mon, 25 Jun 2018
12:10:00 +0000
Today's Research Reports on Trending Tickers: Novavax and Nektar Therapeutics
NEW YORK, NY / ACCESSWIRE / June 25, 2018 / U.S. markets were mixed Friday, with the Dow snapping an eight day losing streak as energy shares rallied. However, major indexes experienced weekly losses on ...
Sun, 24 Jun 2018
11:17:00 +0000
3 Stocks That Could Make You Rich
The road to riches might be paved with buying stocks like these.
Sat, 16 Jun 2018
11:33:00 +0000
Are These 2 Dark Horse Vaccine Makers Worth the Risk?
A new industry report suggests that Novavax and Inovio Pharmaceuticals might be grossly undervalued right now.
Fri, 15 Jun 2018
15:12:23 +0000
Why Novavax Sees a Huge Opportunity in Its Influenza Vaccine
Novavax (NVAX) expects the seasonal influenza vaccine market in the world’s top seven markets to grow from ~$3.2 billion in the 2012–2013 season to $5.3 billion by the 2021–2022 season. Influenza is an infectious disease that causes illness in humans, ranging from mild to life-threatening symptoms or death. Largely in part due to infection by unique strains of influenza for which most people have not developed protective antibodies, serious illness occurs in susceptible populations (such as the elderly and very young) as well as the general population.
Fri, 15 Jun 2018
15:12:23 +0000
Novavax’s Cash Flow Trends
Novavax (NVAX) completed a public offering of ~34.9 million shares of its common stock in April. Through this offering, the company raised ~$54 million. In the first quarter, Novavax sold 15.7 million of its common shares, raising $32.3 million in net proceeds. Its number of outstanding shares is expected to rise to ~400 million from ~262 million between fiscal 2015 and fiscal 2019.
Fri, 15 Jun 2018
15:12:23 +0000
Analyzing Novavax’s Financial Performance
Novavax (NVAX) generates revenue in the form of grants from the Bill and Melinda Gates Foundation (or BMGF) for the development of its RSV F (respiratory syncytial virus fusion protein) vaccine for infants via maternal immunization. During the first quarter of fiscal 2018, the company’s revenue rose YoY (year-over-year) to $9.7 million from $5.7 million. The BMGF awarded an $89.1 million grant to Novavax in 2015, of which the company has recognized $51 million so far.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "I joined almost three years ago and have never been sorry. The search features here are terrific." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards